$SPTX News

Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate

HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics Q1 EPS $(10.34) Misses $(9.48) Estimate

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35

Leerink Partners Initiates Coverage On Seaport Therapeutics with Outperform Rating, Announces Price Target of $35

JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42

Stifel Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $30

Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move

Seaport Therapeutics IPO Indicating $25/Share On 670K Shares; IPO Priced At $18/Share On 14.16M Shares

Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

Seaport Therapeutics Pursues IPO On Positive Trial Results